Medicare Part D plans cover popular obesity drugs if they are used for an additional medically accepted purpose as approved ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

礼来公司的股价在2023年初一路飙升，由于投资者押注该药物的受欢迎程度，该公司股价翻了一番。 去年10月， 减肥药 Zepbound的销售情况令人失望，该公司股价下跌，此后一直低迷。

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

周三，尽管制药公司礼来 (NYSE:LLY)第四季度收入未达市场预期，富国银行仍重申了其对礼来股票的"增持"评级和1,000.00美元的目标价。礼来报告的收入为135亿美元，低于约140亿美元的一致预期。

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the ...

The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...